Lead Product(s): Antibodies
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2020
Under the terms of agreement, Novo Nordisk will receive the rights to use several Chugai’s antibody engineering technologies for their research activities and optional rights for the development and marketing of therapeutic antibodies applying those technologies.